These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19661843)

  • 1. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program.
    Bernd H; De Kerviler E; Gaillard S; Bonnemain B
    Invest Radiol; 2009 Jun; 44(6):336-42. PubMed ID: 19661843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data.
    Sharma R; Saini S; Ros PR; Hahn PF; Small WC; de Lange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK; Morris M; Lucas M
    J Magn Reson Imaging; 1999 Feb; 9(2):291-4. PubMed ID: 10077027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent.
    Bourrinet P; Bengele HH; Bonnemain B; Dencausse A; Idee JM; Jacobs PM; Lewis JM
    Invest Radiol; 2006 Mar; 41(3):313-24. PubMed ID: 16481915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study.
    Anzai Y; Piccoli CW; Outwater EK; Stanford W; Bluemke DA; Nurenberg P; Saini S; Maravilla KR; Feldman DE; Schmiedl UP; Brunberg JA; Francis IR; Harms SE; Som PM; Tempany CM;
    Radiology; 2003 Sep; 228(3):777-88. PubMed ID: 12954896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
    Yancy AD; Olzinski AR; Hu TC; Lenhard SC; Aravindhan K; Gruver SM; Jacobs PM; Willette RN; Jucker BM
    J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin and uptake of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) in human monocyte-macrophages: implications for magnetic resonance imaging.
    Müller K; Skepper JN; Tang TY; Graves MJ; Patterson AJ; Corot C; Lancelot E; Thompson PW; Brown AP; Gillard JH
    Biomaterials; 2008 Jun; 29(17):2656-62. PubMed ID: 18377983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging.
    Dinniwell R; Chan P; Czarnota G; Haider MA; Jhaveri K; Jewett M; Fyles A; Jaffray D; Milosevic M
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):844-51. PubMed ID: 19095369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro.
    Müller K; Skepper JN; Posfai M; Trivedi R; Howarth S; Corot C; Lancelot E; Thompson PW; Brown AP; Gillard JH
    Biomaterials; 2007 Mar; 28(9):1629-42. PubMed ID: 17178155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.
    Islam T; Wolf G
    Cancer Biomark; 2009; 5(2):69-73. PubMed ID: 19414923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization?
    Harisinghani MG; Saksena MA; Hahn PF; King B; Kim J; Torabi MT; Weissleder R
    AJR Am J Roentgenol; 2006 Jan; 186(1):144-8. PubMed ID: 16357394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10.
    Raynal I; Prigent P; Peyramaure S; Najid A; Rebuzzi C; Corot C
    Invest Radiol; 2004 Jan; 39(1):56-63. PubMed ID: 14701989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience.
    Bellin MF; Roy C; Kinkel K; Thoumas D; Zaim S; Vanel D; Tuchmann C; Richard F; Jacqmin D; Delcourt A; Challier E; Lebret T; Cluzel P
    Radiology; 1998 Jun; 207(3):799-808. PubMed ID: 9609907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours.
    Neuwelt EA; Várallyay P; Bagó AG; Muldoon LL; Nesbit G; Nixon R
    Neuropathol Appl Neurobiol; 2004 Oct; 30(5):456-71. PubMed ID: 15488022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide.
    Herborn CU; Vogt FM; Lauenstein TC; Dirsch O; Corot C; Robert P; Ruehm SG
    J Magn Reson Imaging; 2006 Aug; 24(2):388-93. PubMed ID: 16791857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USPIO-enhanced magnetic resonance imaging for nodal staging in patients with head and neck cancer.
    Curvo-Semedo L; Diniz M; Miguéis J; Julião MJ; Martins P; Pinto A; Caseiro-Alves F
    J Magn Reson Imaging; 2006 Jul; 24(1):123-31. PubMed ID: 16755542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferumoxtran-10 Advanced Magnetics.
    Leenders W
    IDrugs; 2003 Oct; 6(10):987-93. PubMed ID: 14534857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of nanoparticle use in cancer imaging.
    Islam T; Harisinghani MG
    Cancer Biomark; 2009; 5(2):61-7. PubMed ID: 19414922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging.
    Deserno WM; Harisinghani MG; Taupitz M; Jager GJ; Witjes JA; Mulders PF; Hulsbergen van de Kaa CA; Kaufmann D; Barentsz JO
    Radiology; 2004 Nov; 233(2):449-56. PubMed ID: 15375228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging.
    Saini S; Sharma R; Baron RL; Turner DA; Ros PR; Hahn PF; Small WC; Delange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK
    Clin Radiol; 2000 Sep; 55(9):690-5. PubMed ID: 10988047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol.
    Bluemke DA; Weber TM; Rubin D; de Lange EE; Semelka R; Redvanly RD; Chezmar J; Outwater E; Carlos R; Saini S; Holland GA; Mammone JF; Brown JJ; Milestone B; Javitt MC; Jacobs P
    Radiology; 2003 Aug; 228(2):457-64. PubMed ID: 12893904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.